---
schema_version: "secwatch.filing_event.v1"
accession: "0001609550-25-000030"
form_type: "8-K"
ticker: "INSP"
cik: "0001609550"
company_name: "Inspire Medical Systems, Inc."
filed_at: "2025-08-04T23:59:59+00:00"
generated_at: "2026-05-17T21:28:19.069621+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Inspire Medical Q2 net loss $3.6M, cuts FY 2025 revenue guidance to $900-910M

## Summary
- Q2 revenue $217.1M (+11% YoY), net loss $3.6M vs prior year net income $9.8M.
- Adjusted diluted EPS $0.45; GAAP diluted loss per share $0.12.
- FY 2025 revenue guidance cut to $900-910M (prior $940-955M); EPS cut to $0.40-0.50 from $2.20-2.30.
- Full U.S. launch of Inspire V neurostimulation system initiated.
- EVP Randall Ban to retire on January 30, 2026.

## SEC filing metadata
- accession: 0001609550-25-000030
- form_type: 8-K
- ticker: INSP
- cik: 0001609550
- company_name: Inspire Medical Systems, Inc.
- filed_at: 2025-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1609550/000160955025000030/0001609550-25-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1609550/000160955025000030/insp-20250804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001609550-25-000030
- JSON: https://secwatch.observer/filing/0001609550-25-000030.json
- Plain text: https://secwatch.observer/filing/0001609550-25-000030.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.